Instruction for use: Nilutamide (Nilutamidum)

chemical name

5,5-Dimethyl-3- [4-nitro-3- (trifluoromethyl) phenyl] -2,4-imidazolidinedione

Pharmacological group

Androgens, antiandrogens

Antineoplastic hormonal agents and hormone antagonists

Nosological classification (ICD-10)

C61 Malignant neoplasm of prostate

Adenocarcinoma of the prostate, Hormone-dependent prostate cancer, Hormone-Resistant Prostate Cancer, Malignant tumor of prostate, Malignant neoplasm of prostate, Carcinoma of the prostate, Locally-distributed non-metastatic prostate cancer, Locally advanced prostate cancer, Locally spread prostate cancer, Metastatic prostatic carcinoma, Metastatic prostate cancer, Metastatic hormone-resistant prostate cancer, Non-metastatic prostate cancer, Incompatible prostate cancer, Prostate Cancer, Prostate cancer, Common prostate cancer, Testosterone-Depot Prostate Cancer

Code CAS 63612-50-0

Pharmacology

Pharmacological action - antiandrogenic, antitumor.

Competitively blocks the cellular receptors of androgens, disrupts the binding of dihydrotestosterone and prevents the manifestation of its biological effects in target organs, incl. In tumor cells of the prostate gland - inhibits tumor growth. With a single admission, the effect is maintained for at least 24 hours.

Indications

Prostate cancer (as part of combination therapy), antiandrogenic preparation for sex change in men.

Contraindications

Hypersensitivity, anemia, impaired liver function, lung disease, childhood.

Side effects

Hyperventilation, painful breathing, shortness of breath, interstitial changes in the lungs, appetite disorders and bowel function, nausea, vomiting, paleness of the hands and ankles, pain in the lower parts of the hands and feet, visual disorders (in particular, weakening adaptation in the dark), sensation of hot flashes , Shortness of breath, signs of liver dysfunction (itchy skin, darkening of urine, jaundice, pain in the right side of the trunk, flu-like syndrome, increased bilirubin and transaminases), anemia.

Interaction

Enhances the effect of phenytoin, propranolol, chlordiazepoxide, lidocaine, diazepam, theophylline.

Routes of administration

Inside.

Precautions

With the development of violations of respiratory function, a dose reduction or complete withdrawal of the drug is necessary. Treatment should be discontinued when clinical and laboratory signs of toxic damage to the liver and pain, suggesting the presence of thrombosis. During the period of therapy, alcohol intake should be avoided, a "disulfiramic reaction" (palpitation, malaise, nausea, vomiting) is possible. To improve the light adaptation is recommended wearing glasses with darkened glasses. It is prohibited to drive vehicles during the course of treatment.